Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorpromazine Effect on Esophageal Sensitivity
NCT03183310Unknown
- Sponsor
- UZ Leuven
- Start
- Jul 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Chlorpromazine with Placebo (2 arms). Primary endpoints: Change in temperature sensitivity at 30 months, Change in mechanical sensitivity at 30 months and 2 more. Status: unknown.
02
Drugs
Aminazin
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03183310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03183310.